2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka
Executive Summary
Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.
You may also be interested in...
Deals Of The Week: Exit From Ambit Tie-Up Just A Blip In Astellas’ Oncology Aspirations
DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.
Will Mirabegron Pass Muster In Overactive Bladder?
Astellas aims to muscle in to a growing disease space dominated by muscarinic receptor agonists with its beta-3 agonist mirabegron (YM178) – but first it must get by an FDA advisory committee review.
Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: